Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
pylori in GI malignancies and anaerobic bacterial species like Fusobacterium and Bacteroides fragilis in CRC are the two examples of direct connection ( Candida albicans and Fusobacterium nucleatum ( 2 Gut microbiome and micronutrients in cancer According to the statistical data from the International Agency for Research on Cancer (IARC), factors such as poor diet, lifestyle, smoking alongside overpopulation and aging, are expected to significantly escalate the worldwide burden of cancer by 2030 ( 2.1 Interactions between fat soluble vitamins, gut microbiome and cancer 2.1.1 Vitamin A The human GI tract provides a hospitable environment for a diverse array of microbes
Affordable pricing with package options available
How Moonshot Medical Sources BPC-157 Moonshot Medical works with a licensed 503A compounding pharmacy that provides pharmaceutical-grade BPC-157
Useful investigations include: Cytokine panels to assess ongoing inflammatory activation Lymphocyte subset analysis to characterize immune dysfunction patterns Organic acid testing to evaluate mitochondrial function and cellular energy metabolism Comprehensive stool analysis to assess microbiome status and intestinal permeability Cortisol and adrenal function testing Viral reactivation panels including EBV and CMV antibody titer tests Autonomic function testing, including heart rate variability analysis, and Advanced nutrient status including glutathione, CoQ10, NAD+ markers, B vitamins, and magnesium This holistic picture of your health allows for targeted interventions rather than generic symptom management, fostering more effective long COVID treatment
Regulatory status: unapproved and research-use-only As of the preparation of this article, BPC-157 has not received marketing authorization from the US Food and Drug Administration, the European Medicines Agency, or equivalent national regulators for any therapeutic indication
Journal of Clinical Pharmacy and Therapeutics, 46 (5), 1184-1191
&srotate=0)
